Karyopharm Therapeutics (KPTI) Tops Q3 EPS by 2c

Karyopharm Therapeutics (NASDAQ: KPTI) reported Q3 EPS of ($0.85), $0.02 better than the analyst estimate of ($0.87).

For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.

You May Also Be Interested In

• Karyopharm Therapeutics (KPTI) Misses Q2 EPS by $1.01, Beats on Revenue; Offers FY26 Revenue Guidance
• Boxlight Corporation (BOXL) Tops Q2 EPS by 2050c
• Jefferies sees a buying opportunity in this S&P 500 sector